>
Switch to:

Opiant Pharmaceuticals PE Ratio

: At Loss (As of Today)
View and export this data going back to 2007. Start your Free Trial

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2021-10-27), Opiant Pharmaceuticals's share price is $23.38. Opiant Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 was $-0.36. Therefore, Opiant Pharmaceuticals's PE Ratio for today is At Loss.


The historical rank and industry rank for Opiant Pharmaceuticals's PE Ratio or its related term are showing as below:

NAS:OPNT' s PE Ratio Range Over the Past 10 Years
Min: At Loss   Med: 5.82   Max: 92.63
Current: At Loss

At Loss
92.63

During the past 13 years, the highest PE Ratio of Opiant Pharmaceuticals was 92.63. The lowest was 0.00. And the median was 5.82.


NAS:OPNT's PE Ratio is ranked lower than
99.99% of the 30 Companies
in the Biotechnology industry.

( Industry Median: 34.65 vs. NAS:OPNT: At Loss )

Opiant Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Jun. 2021 was $0.31. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 was $-0.36.

As of today (2021-10-27), Opiant Pharmaceuticals's share price is $23.38. Opiant Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2021 was $-0.36. Therefore, Opiant Pharmaceuticals's PE Ratio without NRI for today is At Loss.

During the past 13 years, Opiant Pharmaceuticals's highest PE Ratio without NRI was 92.63. The lowest was 0.00. And the median was 5.82.

Opiant Pharmaceuticals's EPS without NRI for the three months ended in Jun. 2021 was $0.31. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2021 was $-0.36.

During the past 12 months, Opiant Pharmaceuticals's average EPS without NRI Growth Rate was -121.10% per year.

During the past 13 years, Opiant Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 31.40% per year. The lowest was -44.20% per year. And the median was 12.00% per year.

Opiant Pharmaceuticals's EPS (Basic) for the three months ended in Jun. 2021 was $0.39. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2021 was $-0.26.


Opiant Pharmaceuticals PE Ratio Historical Data

The historical data trend for Opiant Pharmaceuticals's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Opiant Pharmaceuticals Annual Data
Trend Jul11 Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Dec18 Dec19 Dec20
PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss 4.42 At Loss 6.64 At Loss

Opiant Pharmaceuticals Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.28 At Loss At Loss At Loss At Loss

Competitive Comparison

For the Biotechnology subindustry, Opiant Pharmaceuticals's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Opiant Pharmaceuticals PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Opiant Pharmaceuticals's PE Ratio distribution charts can be found below:

* The bar in red indicates where Opiant Pharmaceuticals's PE Ratio falls into.



Opiant Pharmaceuticals PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Opiant Pharmaceuticals's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=23.38/-0.360
=At Loss

Opiant Pharmaceuticals's Share Price of today is $23.38.
Opiant Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.36.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio or PE Ratio (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Opiant Pharmaceuticals  (NAS:OPNT) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Opiant Pharmaceuticals PE Ratio Related Terms

Thank you for viewing the detailed overview of Opiant Pharmaceuticals's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Opiant Pharmaceuticals Business Description

Opiant Pharmaceuticals logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
233 Wilshire Blvd, Suite 280, Santa Monica, CA, USA, 90401
Opiant Pharmaceuticals Inc is a specialty pharmaceutical company operating in the US. It develops pharmacological treatments for substance use, addictive and eating disorders. The company has developed NARCAN, a Nasal Spray for treatment to reverse opioid overdoses. The company's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), Opioid Use Disorder (OUD) and Acute Cannabinoid Overdose (ACO). The majority of the revenue is generated in the form of Royalty and licensing.
Executives
Thomas Thomas T. director C/O OPIANT PHARMACEUTICALS, INC. 401 WILSHIRE BOULEVARD, 12TH FLOOR SANTA MONICA CA 90401
Sinclair Michael director, 10 percent owner 86 GLOUCESTER PLACE LONDON XX W1U6HP
Collard Craig A director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Daly Richard J director 355 ALHAMBRA CIRCLE SUITE 1500 CORAL GABLES FL 33134
Macdougall Ann L. director C/O OPIANT PHARMACEUTICALS, INC. 401 WILSHIRE BOULEVARD, 12TH FLOOR SANTA MONICA CA 90401
Silver Gabrielle Alison director C/O OPIANT PHARMACEUTICALS, INC. 401 WILSHIRE BOULEVARD, 12TH FLOOR SANTA MONICA CA 90401
Gorman Brian other: General Counsel 233 WILSHIRE BLVD SUITE 280 SANTA MONICA CA 90401
Skolnick Phil officer: Chief Scientific Officer C/O DOV PHARMACEUTICAL, INC. 433 HACKENSACK AVENUE HACKENSACK NJ 07601
Crystal Roger director, 10 percent owner, officer: Chief Executive Officer 445 PARK AVE 10TH FL. NEW YORK NY 10022
Ellison Mark Jason Heath other: UK Managing Director C/O OPIANT PHARMACEUTICALS, INC. 201 SANTA MONICA BLVD., SUITE 500 SANTA MONICA CA 90401
Thompson Rahsaan other: General Counsel 233 WILSHIRE BOULEVARD SUITE 280 SANTA MONICA CA 90401
Mottiwala Aziz officer: Chief Commercial Officer 233 WILSHIRE BOULEVARD SUITE 280 SANTA MONICA CA 90401
Wolf Geoffrey 10 percent owner 445 PARK AVENUE 10TH FL. NEW YORK NY 10022
Pollack Kevin director, officer: See Remarks 150 RAINVILLE ROAD TARPON SPRINGS FL 34689
Meuse Joseph J director, 10 percent owner 211 FALMOUTH STREET WARRENTON VA 20186

Opiant Pharmaceuticals Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)